| Document Date: 2013-01-09 10:16:30
Open Document File Size: 2,34 MBShare Result on Facebook
City New York / Leuven / Brussels / / Company Successful Ophthalmology Franchise ThromboGenics NV / Roche Cancer ThromboGenics / Jefferies International Limited / KBC Securities / ThromboGenics / Biotech Company / AMD / / Continent Europe / / Country Belgium / United States / / Currency EUR / / Event Business Partnership / FDA Phase / IPO / Company Listing Change / Second Stock Issuance / / Facility Company’s pipeline / Generating Pipeline / / IndustryTerm biotechnology / pharmaceutical industry / treatment of serious visual disorders / attractive product / ophthalmic products / technology transfer success fee / biopharmaceutical / pharmaceutical market / treatment of back of the eye disease / treatment of eye disease / / MarketIndex Next 150 / / MedicalCondition macular degeneration / Roche Cancer ThromboGenics / Age-related Macular Degeneration / macular hole / diabetic retinopathy / Anti-PlGF cancer / disease / serious visual disorders / advanced cancer / advanced solid tumours / Deep vein thrombosis / diseases / Diabetic Macular Edema / Atrial Fibrillation / eye disease / thrombosis / eye diseases / / MedicalTreatment Surgical Treatment / surgery / non-surgical treatment / eye surgery / knee replacement surgery / knee surgery / total knee replacement / / Organization Emerging Force / American Society of Retina Specialists / / Person Given / / Position CEO / Global Coordinator / / Product IntraVitreous Injection / Microplasmin / TB-402 / DR / TB-403 / Europe / / PublishedMedium Ophthalmology / / Technology biotechnology / /
SocialTag |
THROMcover Corpo EN+NL 02.indd